Analyst Research Report Snapshot

Title:

Cipla Ltd. (CIPLA) - Qtr. Update - Dtd. - November 05, 2012

Price:

$23.00

Provider:

Axis Capital Limited

Date:

05 Nov 2012

Pages:

3

Type:

AcrobatPDF

Companies referenced:

CIPL.NS

Available for Immediate Download
Summary:

Cipla’s Q2FY13 revenue (Rs 22 bn; up 23% YoY led by 38% YoY growth in export formulations) and adj. PAT (Rs 4.7 bn; up 61% YoY excluding forex gain of Rs 260 mn) were 10% and 20% above our estimates respectively. Strong performance was led by: (a) full impact of Lexapro supplies to Teva, (b) beginning of Dymista supplies to Meda, and (c) 405 bps YoY expansion in gross margin (product-mix improvement, price hike in few therapies/ geographies and currency benefits). Management guided for 15%+ revenue growth (>Rs 80 bn; our estimate of Rs 81 bn) in FY13. Current EBITDA margin of 31% in Q2 is not sustainable as Lexapro exclusivity has ended, however benefits of product-mix rationalization and higher prices would continue (we build in 27%/26% margin in FY13/ FY14). Management indicated there are more Lexapro-like products to be launched (by partners/ Cipla). Domestic formulations grew 14% YoY; expects to sustain 17-18% growth led by key therapies like respiratory, CVS and anti-biotic. Maintain BUY with TP of Rs 428 (13% upside from CMP) We raise our FY13E/ FY14E EPS by 12%/9% to Rs 19/ Rs 21 to factor in higher EBITDA margin. Consequently, revise TP to Rs 428 (20x FY14E EPS) vs. Rs 391 earlier. Further upside likely from commercialization of inhalers in Europe, ramp-up of Dymista in US /other geographies, launch of blockbuster products like Lexapro (by partners/ Cipla). Pick-up in domestic formulation growth is also a positive sign as it helps in sustaining margins and cash flow generation. Further, USD 5 bn of aspirational revenue target by 2020 (implying 16% CAGR over 2012-20) gives a strong directional indication. Maintain BUY. At CMP of Rs 380, the stock trades at 20x FY13E EPS and 18x FY14E EPS. Regards, Deepak Khetan (Asst VP – Life Sciences) Institutional Equity Research Axis Capital Ltd. Tel: +91 22 4325 1132

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.